The BMS is delighted with news that the MHRA has licensed fezolinetant for the treatment of moderate to severe vasomotor symptoms.

Vasomotor symptoms (VMS) can have a significant impact on many women, with more than 75% experiencing VMS and a quarter describing their symptoms as severe. A third of women experience long-term symptoms, which may last as much as seven years or longer.

Having access to fezolinetant, a new non-hormonal treatment option, will increase the choice available to women, particularly those who can’t take HRT or do not wish to take it.  It is likely to offer many women experiencing VMS considerable improvement in their day-to-day quality of life.